nodes	percent_of_prediction	percent_of_DWPC	metapath
Nimodipine—CYP3A5—Ifosfamide—testicular cancer	0.101	0.419	CbGbCtD
Nimodipine—CYP3A5—Etoposide—testicular cancer	0.048	0.2	CbGbCtD
Nimodipine—CYP3A4—Ifosfamide—testicular cancer	0.0392	0.163	CbGbCtD
Nimodipine—CACNA1S—seminal vesicle—testicular cancer	0.0229	0.105	CbGeAlD
Nimodipine—CYP3A4—Vinblastine—testicular cancer	0.0208	0.0866	CbGbCtD
Nimodipine—CACNB3—seminal vesicle—testicular cancer	0.0205	0.0937	CbGeAlD
Nimodipine—CYP3A4—Etoposide—testicular cancer	0.0187	0.078	CbGbCtD
Nimodipine—AHR—seminal vesicle—testicular cancer	0.0152	0.0694	CbGeAlD
Nimodipine—CACNB4—testis—testicular cancer	0.0139	0.0637	CbGeAlD
Nimodipine—CYP3A4—Doxorubicin—testicular cancer	0.0128	0.0532	CbGbCtD
Nimodipine—CACNB1—female gonad—testicular cancer	0.0125	0.0574	CbGeAlD
Nimodipine—CACNB3—female gonad—testicular cancer	0.012	0.055	CbGeAlD
Nimodipine—CACNB1—testis—testicular cancer	0.0111	0.0509	CbGeAlD
Nimodipine—CACNB3—testis—testicular cancer	0.0107	0.0488	CbGeAlD
Nimodipine—NR3C2—seminal vesicle—testicular cancer	0.0101	0.0462	CbGeAlD
Nimodipine—AHR—female gonad—testicular cancer	0.00891	0.0408	CbGeAlD
Nimodipine—CACNB1—lymph node—testicular cancer	0.00807	0.0369	CbGeAlD
Nimodipine—AHR—testis—testicular cancer	0.00791	0.0361	CbGeAlD
Nimodipine—CACNB3—lymph node—testicular cancer	0.00774	0.0354	CbGeAlD
Nimodipine—CACNB2—testis—testicular cancer	0.00717	0.0328	CbGeAlD
Nimodipine—CACNA1D—testis—testicular cancer	0.00627	0.0287	CbGeAlD
Nimodipine—NR3C2—female gonad—testicular cancer	0.00594	0.0271	CbGeAlD
Nimodipine—CACNA1C—testis—testicular cancer	0.00579	0.0265	CbGeAlD
Nimodipine—AHR—lymph node—testicular cancer	0.00573	0.0262	CbGeAlD
Nimodipine—Phlebitis—Dactinomycin—testicular cancer	0.0054	0.00998	CcSEcCtD
Nimodipine—NR3C2—testis—testicular cancer	0.00527	0.0241	CbGeAlD
Nimodipine—CACNB2—lymph node—testicular cancer	0.0052	0.0238	CbGeAlD
Nimodipine—Lactic dehydrogenase activity increased—Epirubicin—testicular cancer	0.00508	0.00939	CcSEcCtD
Nimodipine—Phlebitis—Ifosfamide—testicular cancer	0.00495	0.00915	CcSEcCtD
Nimodipine—Wheezing—Cisplatin—testicular cancer	0.00492	0.00909	CcSEcCtD
Nimodipine—Jaundice—Chlorambucil—testicular cancer	0.00484	0.00895	CcSEcCtD
Nimodipine—Fluid retention—Cisplatin—testicular cancer	0.00481	0.00888	CcSEcCtD
Nimodipine—Lactic dehydrogenase activity increased—Doxorubicin—testicular cancer	0.0047	0.00869	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Etoposide—testicular cancer	0.00464	0.00857	CcSEcCtD
Nimodipine—Deep vein thrombosis—Methotrexate—testicular cancer	0.00457	0.00844	CcSEcCtD
Nimodipine—CACNA1D—lymph node—testicular cancer	0.00454	0.0208	CbGeAlD
Nimodipine—Depression—Vinblastine—testicular cancer	0.00454	0.00839	CcSEcCtD
Nimodipine—Blood lactate dehydrogenase increased—Epirubicin—testicular cancer	0.00447	0.00827	CcSEcCtD
Nimodipine—Liver function test abnormal—Dactinomycin—testicular cancer	0.0043	0.00794	CcSEcCtD
Nimodipine—Phlebitis—Cisplatin—testicular cancer	0.00427	0.00788	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Ifosfamide—testicular cancer	0.00426	0.00788	CcSEcCtD
Nimodipine—CACNA1C—lymph node—testicular cancer	0.00419	0.0192	CbGeAlD
Nimodipine—Blood lactate dehydrogenase increased—Doxorubicin—testicular cancer	0.00414	0.00765	CcSEcCtD
Nimodipine—Cardiac failure congestive—Cisplatin—testicular cancer	0.00405	0.00749	CcSEcCtD
Nimodipine—Phlebitis—Etoposide—testicular cancer	0.00391	0.00722	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Etoposide—testicular cancer	0.00387	0.00715	CcSEcCtD
Nimodipine—NR3C2—lymph node—testicular cancer	0.00382	0.0175	CbGeAlD
Nimodipine—Cardiac failure congestive—Etoposide—testicular cancer	0.00371	0.00686	CcSEcCtD
Nimodipine—Hyponatraemia—Cisplatin—testicular cancer	0.00369	0.00682	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Cisplatin—testicular cancer	0.00368	0.00679	CcSEcCtD
Nimodipine—Ileus—Epirubicin—testicular cancer	0.00367	0.00679	CcSEcCtD
Nimodipine—Anaemia—Chlorambucil—testicular cancer	0.00359	0.00663	CcSEcCtD
Nimodipine—Ileus—Doxorubicin—testicular cancer	0.0034	0.00628	CcSEcCtD
Nimodipine—Cramp muscle—Cisplatin—testicular cancer	0.00331	0.00612	CcSEcCtD
Nimodipine—Anaemia—Vinblastine—testicular cancer	0.00329	0.00608	CcSEcCtD
Nimodipine—Hepatitis—Dactinomycin—testicular cancer	0.00322	0.00595	CcSEcCtD
Nimodipine—CYP3A5—female gonad—testicular cancer	0.00321	0.0147	CbGeAlD
Nimodipine—Flushing—Bleomycin—testicular cancer	0.0032	0.00592	CcSEcCtD
Nimodipine—Hepatobiliary disease—Ifosfamide—testicular cancer	0.00311	0.00574	CcSEcCtD
Nimodipine—Thrombocytopenia—Chlorambucil—testicular cancer	0.0031	0.00573	CcSEcCtD
Nimodipine—Sweating increased—Cisplatin—testicular cancer	0.00309	0.00572	CcSEcCtD
Nimodipine—Hypertension—Vinblastine—testicular cancer	0.00307	0.00568	CcSEcCtD
Nimodipine—Cramp muscle—Etoposide—testicular cancer	0.00303	0.0056	CcSEcCtD
Nimodipine—Bradycardia—Ifosfamide—testicular cancer	0.003	0.00555	CcSEcCtD
Nimodipine—Flushing—Dactinomycin—testicular cancer	0.00299	0.00552	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Etoposide—testicular cancer	0.00297	0.00549	CcSEcCtD
Nimodipine—Hepatitis—Ifosfamide—testicular cancer	0.00295	0.00545	CcSEcCtD
Nimodipine—Thrombocytopenia—Vinblastine—testicular cancer	0.00284	0.00525	CcSEcCtD
Nimodipine—Sweating increased—Etoposide—testicular cancer	0.00284	0.00524	CcSEcCtD
Nimodipine—Anaemia—Bleomycin—testicular cancer	0.00278	0.00513	CcSEcCtD
Nimodipine—Flushing—Ifosfamide—testicular cancer	0.00274	0.00506	CcSEcCtD
Nimodipine—Cardiac disorder—Ifosfamide—testicular cancer	0.00274	0.00506	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00274	0.00505	CcSEcCtD
Nimodipine—Hepatobiliary disease—Cisplatin—testicular cancer	0.00268	0.00495	CcSEcCtD
Nimodipine—Angiopathy—Ifosfamide—testicular cancer	0.00268	0.00495	CcSEcCtD
Nimodipine—Immune system disorder—Ifosfamide—testicular cancer	0.00266	0.00492	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Epirubicin—testicular cancer	0.0026	0.00481	CcSEcCtD
Nimodipine—Anaemia—Dactinomycin—testicular cancer	0.00259	0.00479	CcSEcCtD
Nimodipine—Bradycardia—Cisplatin—testicular cancer	0.00259	0.00478	CcSEcCtD
Nimodipine—Myalgia—Bleomycin—testicular cancer	0.00256	0.00473	CcSEcCtD
Nimodipine—Jaundice—Etoposide—testicular cancer	0.00253	0.00467	CcSEcCtD
Nimodipine—Fluid retention—Epirubicin—testicular cancer	0.00247	0.00456	CcSEcCtD
Nimodipine—Hepatobiliary disease—Etoposide—testicular cancer	0.00245	0.00454	CcSEcCtD
Nimodipine—Oedema—Bleomycin—testicular cancer	0.00245	0.00453	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Doxorubicin—testicular cancer	0.00241	0.00445	CcSEcCtD
Nimodipine—Thrombocytopenia—Bleomycin—testicular cancer	0.0024	0.00444	CcSEcCtD
Nimodipine—Myalgia—Dactinomycin—testicular cancer	0.00239	0.00441	CcSEcCtD
Nimodipine—Anaemia—Ifosfamide—testicular cancer	0.00237	0.00439	CcSEcCtD
Nimodipine—Flushing—Cisplatin—testicular cancer	0.00236	0.00436	CcSEcCtD
Nimodipine—Cardiac disorder—Cisplatin—testicular cancer	0.00236	0.00436	CcSEcCtD
Nimodipine—Hypersensitivity—Chlorambucil—testicular cancer	0.00233	0.00431	CcSEcCtD
Nimodipine—Immune system disorder—Cisplatin—testicular cancer	0.0023	0.00424	CcSEcCtD
Nimodipine—Hypotension—Bleomycin—testicular cancer	0.00229	0.00423	CcSEcCtD
Nimodipine—Oedema—Dactinomycin—testicular cancer	0.00229	0.00423	CcSEcCtD
Nimodipine—Fluid retention—Doxorubicin—testicular cancer	0.00228	0.00422	CcSEcCtD
Nimodipine—Palpitations—Ifosfamide—testicular cancer	0.00227	0.00419	CcSEcCtD
Nimodipine—Pruritus—Chlorambucil—testicular cancer	0.00224	0.00414	CcSEcCtD
Nimodipine—Thrombocytopenia—Dactinomycin—testicular cancer	0.00224	0.00414	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00223	0.00413	CcSEcCtD
Nimodipine—Hypertension—Ifosfamide—testicular cancer	0.00222	0.0041	CcSEcCtD
Nimodipine—Phlebitis—Epirubicin—testicular cancer	0.00219	0.00405	CcSEcCtD
Nimodipine—Dyspnoea—Bleomycin—testicular cancer	0.00219	0.00404	CcSEcCtD
Nimodipine—Myalgia—Ifosfamide—testicular cancer	0.00219	0.00404	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Epirubicin—testicular cancer	0.00217	0.00401	CcSEcCtD
Nimodipine—Diarrhoea—Chlorambucil—testicular cancer	0.00217	0.00401	CcSEcCtD
Nimodipine—Flushing—Etoposide—testicular cancer	0.00216	0.004	CcSEcCtD
Nimodipine—Cardiac disorder—Etoposide—testicular cancer	0.00216	0.004	CcSEcCtD
Nimodipine—Hypersensitivity—Vinblastine—testicular cancer	0.00214	0.00395	CcSEcCtD
Nimodipine—Muscle spasms—Cisplatin—testicular cancer	0.00213	0.00393	CcSEcCtD
Nimodipine—Angiopathy—Etoposide—testicular cancer	0.00211	0.00391	CcSEcCtD
Nimodipine—Immune system disorder—Etoposide—testicular cancer	0.0021	0.00389	CcSEcCtD
Nimodipine—Oedema—Ifosfamide—testicular cancer	0.0021	0.00387	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00208	0.00385	CcSEcCtD
Nimodipine—Cardiac failure congestive—Epirubicin—testicular cancer	0.00208	0.00385	CcSEcCtD
Nimodipine—Nervous system disorder—Ifosfamide—testicular cancer	0.00206	0.0038	CcSEcCtD
Nimodipine—Thrombocytopenia—Ifosfamide—testicular cancer	0.00205	0.00379	CcSEcCtD
Nimodipine—Anaemia—Cisplatin—testicular cancer	0.00205	0.00378	CcSEcCtD
Nimodipine—Phlebitis—Doxorubicin—testicular cancer	0.00203	0.00375	CcSEcCtD
Nimodipine—Hyperhidrosis—Ifosfamide—testicular cancer	0.00203	0.00374	CcSEcCtD
Nimodipine—Vomiting—Chlorambucil—testicular cancer	0.00201	0.00372	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Doxorubicin—testicular cancer	0.00201	0.00371	CcSEcCtD
Nimodipine—Diarrhoea—Vinblastine—testicular cancer	0.00199	0.00367	CcSEcCtD
Nimodipine—Hypotension—Ifosfamide—testicular cancer	0.00196	0.00362	CcSEcCtD
Nimodipine—Muscle spasms—Etoposide—testicular cancer	0.00195	0.0036	CcSEcCtD
Nimodipine—Cardiac failure congestive—Doxorubicin—testicular cancer	0.00193	0.00356	CcSEcCtD
Nimodipine—Dizziness—Vinblastine—testicular cancer	0.00192	0.00355	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00191	0.00353	CcSEcCtD
Nimodipine—Hyponatraemia—Epirubicin—testicular cancer	0.0019	0.0035	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Epirubicin—testicular cancer	0.00189	0.00349	CcSEcCtD
Nimodipine—Myalgia—Cisplatin—testicular cancer	0.00188	0.00348	CcSEcCtD
Nimodipine—Nausea—Chlorambucil—testicular cancer	0.00188	0.00348	CcSEcCtD
Nimodipine—Anaemia—Etoposide—testicular cancer	0.00187	0.00346	CcSEcCtD
Nimodipine—Dyspnoea—Ifosfamide—testicular cancer	0.00187	0.00345	CcSEcCtD
Nimodipine—Liver function test abnormal—Methotrexate—testicular cancer	0.00186	0.00344	CcSEcCtD
Nimodipine—Vomiting—Vinblastine—testicular cancer	0.00185	0.00341	CcSEcCtD
Nimodipine—Headache—Vinblastine—testicular cancer	0.00182	0.00336	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00181	0.00334	CcSEcCtD
Nimodipine—Oedema—Cisplatin—testicular cancer	0.00181	0.00334	CcSEcCtD
Nimodipine—Hypersensitivity—Bleomycin—testicular cancer	0.00181	0.00334	CcSEcCtD
Nimodipine—Nervous system disorder—Cisplatin—testicular cancer	0.00177	0.00327	CcSEcCtD
Nimodipine—Thrombocytopenia—Cisplatin—testicular cancer	0.00177	0.00327	CcSEcCtD
Nimodipine—Tachycardia—Cisplatin—testicular cancer	0.00176	0.00326	CcSEcCtD
Nimodipine—Hyponatraemia—Doxorubicin—testicular cancer	0.00175	0.00324	CcSEcCtD
Nimodipine—Hypertension—Etoposide—testicular cancer	0.00175	0.00324	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.00175	0.00323	CcSEcCtD
Nimodipine—Hyperhidrosis—Cisplatin—testicular cancer	0.00175	0.00323	CcSEcCtD
Nimodipine—Liver function test abnormal—Epirubicin—testicular cancer	0.00174	0.00322	CcSEcCtD
Nimodipine—Pruritus—Bleomycin—testicular cancer	0.00173	0.00321	CcSEcCtD
Nimodipine—Nausea—Vinblastine—testicular cancer	0.00172	0.00319	CcSEcCtD
Nimodipine—Hypotension—Cisplatin—testicular cancer	0.00169	0.00312	CcSEcCtD
Nimodipine—Hypersensitivity—Dactinomycin—testicular cancer	0.00168	0.00311	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00166	0.00308	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00165	0.00304	CcSEcCtD
Nimodipine—Thrombocytopenia—Etoposide—testicular cancer	0.00162	0.00299	CcSEcCtD
Nimodipine—Tachycardia—Etoposide—testicular cancer	0.00162	0.00299	CcSEcCtD
Nimodipine—Liver function test abnormal—Doxorubicin—testicular cancer	0.00161	0.00298	CcSEcCtD
Nimodipine—Dyspnoea—Cisplatin—testicular cancer	0.00161	0.00298	CcSEcCtD
Nimodipine—Hyperhidrosis—Etoposide—testicular cancer	0.0016	0.00296	CcSEcCtD
Nimodipine—Diarrhoea—Dactinomycin—testicular cancer	0.00156	0.00289	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00156	0.00288	CcSEcCtD
Nimodipine—Vomiting—Bleomycin—testicular cancer	0.00156	0.00288	CcSEcCtD
Nimodipine—Depression—Methotrexate—testicular cancer	0.00155	0.00286	CcSEcCtD
Nimodipine—Hypotension—Etoposide—testicular cancer	0.00155	0.00286	CcSEcCtD
Nimodipine—Rash—Bleomycin—testicular cancer	0.00155	0.00286	CcSEcCtD
Nimodipine—Dermatitis—Bleomycin—testicular cancer	0.00154	0.00285	CcSEcCtD
Nimodipine—Hypersensitivity—Ifosfamide—testicular cancer	0.00154	0.00285	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00154	0.00285	CcSEcCtD
Nimodipine—Pruritus—Ifosfamide—testicular cancer	0.00148	0.00274	CcSEcCtD
Nimodipine—Dyspnoea—Etoposide—testicular cancer	0.00148	0.00273	CcSEcCtD
Nimodipine—Hepatobiliary disease—Methotrexate—testicular cancer	0.00147	0.00272	CcSEcCtD
Nimodipine—Nausea—Bleomycin—testicular cancer	0.00146	0.00269	CcSEcCtD
Nimodipine—Vomiting—Dactinomycin—testicular cancer	0.00145	0.00269	CcSEcCtD
Nimodipine—Rash—Dactinomycin—testicular cancer	0.00144	0.00266	CcSEcCtD
Nimodipine—Diarrhoea—Ifosfamide—testicular cancer	0.00143	0.00265	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00143	0.00264	CcSEcCtD
Nimodipine—Jaundice—Epirubicin—testicular cancer	0.00142	0.00262	CcSEcCtD
Nimodipine—Hepatitis—Methotrexate—testicular cancer	0.0014	0.00258	CcSEcCtD
Nimodipine—Dizziness—Ifosfamide—testicular cancer	0.00139	0.00256	CcSEcCtD
Nimodipine—Hepatobiliary disease—Epirubicin—testicular cancer	0.00138	0.00254	CcSEcCtD
Nimodipine—Nausea—Dactinomycin—testicular cancer	0.00136	0.00251	CcSEcCtD
Nimodipine—Vomiting—Ifosfamide—testicular cancer	0.00133	0.00246	CcSEcCtD
Nimodipine—Hypersensitivity—Cisplatin—testicular cancer	0.00133	0.00246	CcSEcCtD
Nimodipine—Bradycardia—Epirubicin—testicular cancer	0.00133	0.00246	CcSEcCtD
Nimodipine—Rash—Ifosfamide—testicular cancer	0.00132	0.00244	CcSEcCtD
Nimodipine—Dermatitis—Ifosfamide—testicular cancer	0.00132	0.00244	CcSEcCtD
Nimodipine—Jaundice—Doxorubicin—testicular cancer	0.00131	0.00242	CcSEcCtD
Nimodipine—Hepatitis—Epirubicin—testicular cancer	0.00131	0.00241	CcSEcCtD
Nimodipine—Cardiac disorder—Methotrexate—testicular cancer	0.0013	0.00239	CcSEcCtD
Nimodipine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00127	0.00235	CcSEcCtD
Nimodipine—Angiopathy—Methotrexate—testicular cancer	0.00127	0.00234	CcSEcCtD
Nimodipine—Immune system disorder—Methotrexate—testicular cancer	0.00126	0.00233	CcSEcCtD
Nimodipine—Nausea—Ifosfamide—testicular cancer	0.00124	0.0023	CcSEcCtD
Nimodipine—Diarrhoea—Cisplatin—testicular cancer	0.00124	0.00228	CcSEcCtD
Nimodipine—Bradycardia—Doxorubicin—testicular cancer	0.00123	0.00227	CcSEcCtD
Nimodipine—Hypersensitivity—Etoposide—testicular cancer	0.00122	0.00225	CcSEcCtD
Nimodipine—Cardiac disorder—Epirubicin—testicular cancer	0.00121	0.00224	CcSEcCtD
Nimodipine—Flushing—Epirubicin—testicular cancer	0.00121	0.00224	CcSEcCtD
Nimodipine—Hepatitis—Doxorubicin—testicular cancer	0.00121	0.00223	CcSEcCtD
Nimodipine—Angiopathy—Epirubicin—testicular cancer	0.00118	0.00219	CcSEcCtD
Nimodipine—Immune system disorder—Epirubicin—testicular cancer	0.00118	0.00218	CcSEcCtD
Nimodipine—Pruritus—Etoposide—testicular cancer	0.00117	0.00216	CcSEcCtD
Nimodipine—Vomiting—Cisplatin—testicular cancer	0.00115	0.00212	CcSEcCtD
Nimodipine—Rash—Cisplatin—testicular cancer	0.00114	0.00211	CcSEcCtD
Nimodipine—Dermatitis—Cisplatin—testicular cancer	0.00114	0.0021	CcSEcCtD
Nimodipine—Diarrhoea—Etoposide—testicular cancer	0.00113	0.00209	CcSEcCtD
Nimodipine—Anaemia—Methotrexate—testicular cancer	0.00112	0.00207	CcSEcCtD
Nimodipine—Cardiac disorder—Doxorubicin—testicular cancer	0.00112	0.00207	CcSEcCtD
Nimodipine—Flushing—Doxorubicin—testicular cancer	0.00112	0.00207	CcSEcCtD
Nimodipine—Angiopathy—Doxorubicin—testicular cancer	0.0011	0.00203	CcSEcCtD
Nimodipine—Dizziness—Etoposide—testicular cancer	0.00109	0.00202	CcSEcCtD
Nimodipine—Muscle spasms—Epirubicin—testicular cancer	0.00109	0.00202	CcSEcCtD
Nimodipine—Immune system disorder—Doxorubicin—testicular cancer	0.00109	0.00202	CcSEcCtD
Nimodipine—Nausea—Cisplatin—testicular cancer	0.00107	0.00198	CcSEcCtD
Nimodipine—Vomiting—Etoposide—testicular cancer	0.00105	0.00194	CcSEcCtD
Nimodipine—Anaemia—Epirubicin—testicular cancer	0.00105	0.00194	CcSEcCtD
Nimodipine—Rash—Etoposide—testicular cancer	0.00104	0.00193	CcSEcCtD
Nimodipine—Dermatitis—Etoposide—testicular cancer	0.00104	0.00193	CcSEcCtD
Nimodipine—Headache—Etoposide—testicular cancer	0.00104	0.00192	CcSEcCtD
Nimodipine—Myalgia—Methotrexate—testicular cancer	0.00103	0.00191	CcSEcCtD
Nimodipine—Muscle spasms—Doxorubicin—testicular cancer	0.00101	0.00187	CcSEcCtD
Nimodipine—Palpitations—Epirubicin—testicular cancer	0.001	0.00186	CcSEcCtD
Nimodipine—Nausea—Etoposide—testicular cancer	0.000983	0.00182	CcSEcCtD
Nimodipine—Hypertension—Epirubicin—testicular cancer	0.000981	0.00181	CcSEcCtD
Nimodipine—Nervous system disorder—Methotrexate—testicular cancer	0.000972	0.0018	CcSEcCtD
Nimodipine—Anaemia—Doxorubicin—testicular cancer	0.000972	0.0018	CcSEcCtD
Nimodipine—Thrombocytopenia—Methotrexate—testicular cancer	0.000971	0.00179	CcSEcCtD
Nimodipine—Myalgia—Epirubicin—testicular cancer	0.000968	0.00179	CcSEcCtD
Nimodipine—Hyperhidrosis—Methotrexate—testicular cancer	0.000958	0.00177	CcSEcCtD
Nimodipine—Palpitations—Doxorubicin—testicular cancer	0.00093	0.00172	CcSEcCtD
Nimodipine—Oedema—Epirubicin—testicular cancer	0.000928	0.00171	CcSEcCtD
Nimodipine—Hypotension—Methotrexate—testicular cancer	0.000926	0.00171	CcSEcCtD
Nimodipine—Nervous system disorder—Epirubicin—testicular cancer	0.00091	0.00168	CcSEcCtD
Nimodipine—Thrombocytopenia—Epirubicin—testicular cancer	0.000908	0.00168	CcSEcCtD
Nimodipine—Hypertension—Doxorubicin—testicular cancer	0.000908	0.00168	CcSEcCtD
Nimodipine—Tachycardia—Epirubicin—testicular cancer	0.000905	0.00167	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000903	0.00167	CcSEcCtD
Nimodipine—Hyperhidrosis—Epirubicin—testicular cancer	0.000897	0.00166	CcSEcCtD
Nimodipine—Myalgia—Doxorubicin—testicular cancer	0.000896	0.00165	CcSEcCtD
Nimodipine—Dyspnoea—Methotrexate—testicular cancer	0.000884	0.00163	CcSEcCtD
Nimodipine—Hypotension—Epirubicin—testicular cancer	0.000867	0.0016	CcSEcCtD
Nimodipine—Oedema—Doxorubicin—testicular cancer	0.000858	0.00159	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000856	0.00158	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000845	0.00156	CcSEcCtD
Nimodipine—Nervous system disorder—Doxorubicin—testicular cancer	0.000842	0.00156	CcSEcCtD
Nimodipine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000841	0.00155	CcSEcCtD
Nimodipine—Tachycardia—Doxorubicin—testicular cancer	0.000838	0.00155	CcSEcCtD
Nimodipine—Hyperhidrosis—Doxorubicin—testicular cancer	0.00083	0.00153	CcSEcCtD
Nimodipine—Dyspnoea—Epirubicin—testicular cancer	0.000827	0.00153	CcSEcCtD
Nimodipine—Hypotension—Doxorubicin—testicular cancer	0.000802	0.00148	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000801	0.00148	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000782	0.00145	CcSEcCtD
Nimodipine—Dyspnoea—Doxorubicin—testicular cancer	0.000765	0.00141	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000741	0.00137	CcSEcCtD
Nimodipine—Hypersensitivity—Methotrexate—testicular cancer	0.00073	0.00135	CcSEcCtD
Nimodipine—Pruritus—Methotrexate—testicular cancer	0.000701	0.0013	CcSEcCtD
Nimodipine—Hypersensitivity—Epirubicin—testicular cancer	0.000684	0.00126	CcSEcCtD
Nimodipine—Diarrhoea—Methotrexate—testicular cancer	0.000678	0.00125	CcSEcCtD
Nimodipine—Pruritus—Epirubicin—testicular cancer	0.000656	0.00121	CcSEcCtD
Nimodipine—Dizziness—Methotrexate—testicular cancer	0.000656	0.00121	CcSEcCtD
Nimodipine—Diarrhoea—Epirubicin—testicular cancer	0.000635	0.00117	CcSEcCtD
Nimodipine—Hypersensitivity—Doxorubicin—testicular cancer	0.000632	0.00117	CcSEcCtD
Nimodipine—Vomiting—Methotrexate—testicular cancer	0.00063	0.00116	CcSEcCtD
Nimodipine—Rash—Methotrexate—testicular cancer	0.000625	0.00116	CcSEcCtD
Nimodipine—Dermatitis—Methotrexate—testicular cancer	0.000625	0.00115	CcSEcCtD
Nimodipine—Headache—Methotrexate—testicular cancer	0.000621	0.00115	CcSEcCtD
Nimodipine—Dizziness—Epirubicin—testicular cancer	0.000614	0.00113	CcSEcCtD
Nimodipine—Pruritus—Doxorubicin—testicular cancer	0.000607	0.00112	CcSEcCtD
Nimodipine—Vomiting—Epirubicin—testicular cancer	0.00059	0.00109	CcSEcCtD
Nimodipine—Nausea—Methotrexate—testicular cancer	0.000589	0.00109	CcSEcCtD
Nimodipine—Diarrhoea—Doxorubicin—testicular cancer	0.000587	0.00109	CcSEcCtD
Nimodipine—Rash—Epirubicin—testicular cancer	0.000585	0.00108	CcSEcCtD
Nimodipine—Dermatitis—Epirubicin—testicular cancer	0.000584	0.00108	CcSEcCtD
Nimodipine—Headache—Epirubicin—testicular cancer	0.000581	0.00107	CcSEcCtD
Nimodipine—Dizziness—Doxorubicin—testicular cancer	0.000568	0.00105	CcSEcCtD
Nimodipine—Nausea—Epirubicin—testicular cancer	0.000551	0.00102	CcSEcCtD
Nimodipine—Vomiting—Doxorubicin—testicular cancer	0.000546	0.00101	CcSEcCtD
Nimodipine—Rash—Doxorubicin—testicular cancer	0.000541	0.001	CcSEcCtD
Nimodipine—Dermatitis—Doxorubicin—testicular cancer	0.000541	0.000999	CcSEcCtD
Nimodipine—Headache—Doxorubicin—testicular cancer	0.000538	0.000994	CcSEcCtD
Nimodipine—Nausea—Doxorubicin—testicular cancer	0.00051	0.000942	CcSEcCtD
